Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Chonticha Chanjam"'
Autor:
Juthamas Prawjaeng, Pattara Leelahavarong, Nuttakarn Budtarad, Songyot Pilasant, Chonticha Chanjam, Wanruchada Katchamart, Pongthorn Narongroeknawin, Tasanee Kitumnuaypong
Publikováno v:
BMC Health Services Research, Vol 23, Iss 1, Pp 1-13 (2023)
Abstract Background New biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) all showed greater clinical benefits in the treatment of patients with rheumatoid arthritis (RA) w
Externí odkaz:
https://doaj.org/article/468a5c7f637b40ca804a284ffe446d81
Autor:
Nitichen Kittiratchakool, Disorn Kulpokin, Chonticha Chanjam, Soamarat Vilaiyuk, Sirirat Charuvanij, Gun Phongsamart, Parichat Khaosut, Manasita Tanya, Ratanavadee Nanagara, Sira Nantapaisarn, Pattara Leelahavarong
Publikováno v:
BMJ Open, Vol 10, Iss 9 (2020)
Objectives This study aimed to analyse the cost–utility and budget impact of adding tocilizumab to the standard treatment for patients with refractory systemic juvenile idiopathic arthritis (sJIA) in Thailand.Design Economic evaluation using a deci
Externí odkaz:
https://doaj.org/article/8ee604e121e544749921b3cf4375098a
Autor:
Nuttakarn Budtarad, Juthamas Prawjaeng, Pattara Leelahavarong, Songyot Pilasant, Chonticha Chanjam, Pongthorn Narongroeknawin, Tasanee Kitumnuaypong, Wanruchada Katchamart
ObjectiveTo assess the comparative efficacy and safety of approved biologic disease-modifying antirheumatic drugs (bDMARDs), biosimilars, and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) for patients with rheumatoid arthritis (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20f8e61176086f63f76ff78a8ad452e2
https://doi.org/10.1101/2023.01.20.23284852
https://doi.org/10.1101/2023.01.20.23284852
Autor:
Ratanavadee Nanagara, Nitichen Kittiratchakool, Parichat Khaosut, Soamarat Vilaiyuk, Sirirat Charuvanij, Sira Nantapaisarn, Pattara Leelahavarong, Manasita Tanya, Gun Phongsamart, Chonticha Chanjam, Disorn Kulpokin
Publikováno v:
BMJ Open
BMJ Open, Vol 10, Iss 9 (2020)
BMJ Open, Vol 10, Iss 9 (2020)
ObjectivesThis study aimed to analyse the cost–utility and budget impact of adding tocilizumab to the standard treatment for patients with refractory systemic juvenile idiopathic arthritis (sJIA) in Thailand.DesignEconomic evaluation using a decisi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f8a44b91e86984f970888a6700ec4cf
https://doi.org/10.1136/bmjopen-2020-037588
https://doi.org/10.1136/bmjopen-2020-037588